Showing results (311-320 of 909) with videos related to

Sort By:
Pageof 91
Journal of the American Society of Nephrology : JASN|August 25, 2006
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarctionPowell Jose, Hicham Skali, Nagesh Anavekar, et al.
The American Journal of Medicine|February 15, 2003
Value of the electrocardiogram in predicting left ventricular enlargement and dysfunction after myocardial infarctionCostantina Manes, Marc A Pfeffer, John D Rutherford, et al.
The American Journal of Cardiology|April 22, 2011
Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery diseaseOrly Vardeny, Hajime Uno, Eugene Braunwald, et al.
European Journal of Internal Medicine|October 30, 2023
Long-term cardiovascular events, graft failure, and mortality in kidney transplant recipientsCharlotte Andersson, Ditte Hansen, Søren Schwartz Sørensen, et al.
The New England Journal of Medicine|August 27, 2021
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 DiabetesBertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, et al.
Circulation|February 23, 2005
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failureWilliam S Weintraub, Zefeng Zhang, Elizabeth M Mahoney, et al.
European Heart Journal|January 13, 2022
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisRajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, et al.
ESC Heart Failure|May 17, 2018
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DNBertram Pitt, George L Bakris, Matthew R Weir, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 31, 2023
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registryPeter Moritz Becher, Gianluigi Savarese, Lina Benson, et al.
Circulation. Heart Failure|May 2, 2020
Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS TrialJoão Pedro Ferreira, Romain Eschalier, Kevin Duarte, et al.
Pageof 91